ICON Cancer Centre
Some information on this page may be available only to Healthcare Professionals. Please

About

Icon Cancer Centre Singapore provides a holistic approach to cancer care, aligning each stage of a patient’s cancer journey with the information and support they need from screening, diagnosis, through to treatment and beyond.

Icon Cancer Centre is part of Icon Group – Australia’s largest dedicated provider of cancer care, with a growing reach into Asia and New Zealand.

Icon Cancer Centre in Singapore has a strong and prominent team of 10 medical oncologists, two haematologists and two radiation oncologists who have received specialist training and worked in world-renowned cancer centres. They are dedicated to delivering personalised, comprehensive evidence-based treatment to support patients and their families through their cancer treatment.

The centre treats a wide-range of cancers with an integrated approach, offering chemotherapy, immunotherapy, targeted therapy, treatment for blood disorders, and radiation therapy services alongside hospital partners. Icon also offers paediatric oncology to treat a wide range of childhood cancers and also operates a dedicated Young Women’s Cancer Program and palliative medicine services to further support cancer patients throughout their cancer journey. In 2021, Icon introduced surgical oncology services at Singapore’s Mount Alvernia Medical Centre, which sees a collegiate group of surgical oncologists specialising in a wide range of cancer types and complex surgical procedures to ensure patients can access the full spectrum of cancer treatment within the one location at Mount Alvernia.

In addition to Icon Cancer Centre services, Icon operates a dedicated health screening clinic - Icon Health Screening - which offers comprehensive screening for a wide range of health conditions and further augments Icon’s holistic approach to cancer care. Their centres provide a friendly environment for patients and their loved ones, combined with technology and evidence-based treatment options delivered by a caring medical team sensitive of the personal and cultural needs of patients and their loved ones.

Oncology services

  • Chemotherapy

  • Targeted therapies

  • Immunotherapy

  • Treatment for blood disorders

  • Radiation therapy

  • Paediatric oncology

  • Surgical oncology

  • Clinical trials and research

Icon Cancer Centre delivers one of the largest private clinical trials programmes in Singapore and is backed by Icon Group’s long-standing research and clinical trials team based in Australia, which has more than 35 years of experience in the delivery of oncology trials. With a dedicated Singapore Director of Clinical Trials and a local medical research committee, Icon continues to bring new emerging treatments and clinical trials to Singapore.

Branches

9

Farrer Park

1 Farrer Park Station Road, #09-13 to 20 Farrer Park Medical Centre, Connexion Singapore 217562

Mount Alvernia

820 Thomson Road #05-03/04 Mt Alvernia Medical Centre Blk A Singapore 574623

Mount Alvernia – Surgical Oncology

820 Thomson Road #01-06, Mt Alvernia Medical Centre Blk A, Singapore 574623

Novena II

38 Irrawaddy Road #07-28 Mount Elizabeth Novena Specialist Centre Singapore 329563

Orchard

3 Mount Elizabeth #13-09/10 Mt Elizabeth Medical Centre Singapore 228510

Gleneagles

6 Napier Road #05-11/12 Gleneagles Medical Centre Singapore 258499

Icon Haematology Centre Mount Elizabeth

3 Mount Elizabeth, #17-03/04 Medical Centre, 228510, Singapore 228510

Mount Elizabeth

3 Mount Elizabeth #17-03/04 Mt Elizabeth Medical Centre Singapore 228510

Novena I

#06-24/25/36 Mt Elizabeth Novena Specialist Centre 38 Irrawaddy Road Singapore 329563

Ongoing trials at ICON Cancer Centre

5 trials shown

Calculating matches

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers li

Study number:
NCT05338970
Cohorts:
2
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.

Study number:
NCT05002127
Cohorts:
1
Study phase:
2, 3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy, Chemotherapy
Calculating matches

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC wi

Study number:
NCT04685135
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Chemotherapy, Biomarker
Calculating matches

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-lin

Study number:
NCT04793958
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of respo

Study number:
NCT03888105
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy